The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...

Former Columbia University psychiatrist Bret Rutherford, MD, committed research misconduct by "falsely reporting that all ...